-
Cara Therapeutics Top-Line Data Disappoints: 'This Is Why You Do Phase 2'
Friday, June 30, 2017 - 9:31am | 505Read More...Shares of Cara Therapeutics Inc (NASDAQ: CARA) fell nearly 30 percent early Friday morning after the company released concerning top-line results from a phase 2B trial of its oral CR845 therapy for the treatment of pain associated with osteoarthritis of the hip or knee. But not all analysts are...
-
Cara Therapeutics' 15% Surge, Explained
Tuesday, March 28, 2017 - 8:58am | 542Read More...Shares of Cara Therapeutics Inc (NASDAQ: CARA), a small-cap clinical-stage bio-pharmaceutical company that develops therapies to alleviate pain, gained more than 15 percent early Tuesday morning after the company announced encouraging results from Part A of a Phase 2/3 trial. Cara has been...
-
FDA Places Cara Therapeutics' Pain Trial On Clinical Hold, Shares Plunge 42%
Friday, February 26, 2016 - 8:35am | 237Read More...Cara Therapeutics Inc (NASDAQ: CARA), a clinical-stage bio-pharmaceutical company that focuses on the development of chemical entities to alleviate pain and pruritus, announced a business update after Thursday's market close. Cara Therapeutics said that the U.S. Food and Drug Administration has...
